Navigation Links
SeqWright's Clinical Trial Support Contributes to the Approval of Two HPV Diagnostic Systems

HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in preparation for FDA submission. Both tests were recently awarded FDA premarket approval. According to Hologic, their Cervista HPV HR clinical trial involved over 4,000 women spread across 89 sites throughout the United States and constituted one of the largest and most demographically diverse clinical trials ever conducted in the United States.

SeqWright was selected to perform the sequencing-based validations of Hologic's HPV Diagnostics assays after successfully completing several of Hologic's previous clinical trials, which all led to FDA approvals. SeqWright maintains advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.

Sequencing for Hologic's clinical trials was performed under GLP guidelines (4X-bidirectional sequencing, stringent controls, full documentation) and all samples were continuously tracked and monitored. The bioinformatics provided by SeqWright were also vital to trial success and were used to implement Hologic's HPV genotyping analysis as well as to create a customized clinical trial decision tree algorithm. These services led to a streamlined, reliable and efficient testing regimen in support of Hologic's two recently approved HPV Diagnostics.

SeqWright CEO, Dr. Fei Lu, M.D. stated, "We wish to congratulate Hologic on the pre-market approvals of their new HPV diagnostic tests and we are proud of the work we performed in support of their efforts."

About SeqWright:

SeqWright Incorporated is a world-class genomic services support organization based in Houston, TX with more than fifteen years of experience specializing in state of the art Molecular Biology and Genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright and its services, please visit

SOURCE SeqWright Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
(Date:10/12/2015)... This study focuses on China,s Genome-Based ... decades, the industry has been growing at a fast pace. ... consumptions in China have transformed ... is one of the world,s major producers for ... world, China is the world,s fastest ...
(Date:10/12/2015)... -- About epilepsy --> ... disorders manifested by benign to severe, disabling, and life-threatening ... malformations and tumors to meningitis, high-risk pregnancies, and trauma ... is unidentified, as is witnessed in the majority of ... between the inhibitory and excitatory signals of the brain, ...
(Date:10/12/2015)... Oct. 12, 2015 A new computer program ... can predict whether they will develop effective language skills ... a study in the journal Brain and Behavior ... In the journal,s Oct. 12 online edition, researchers ... program determines how specific regions of the brain respond ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... 2015 , ... FEI Behavioral Health, a social enterprise with ... management, will present a session at the Wisconsin Society for Human Resource Management ... Chief Operating Officer Daniel Potterton will present an informative workshop, “Training HR to ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... part of a contact channel benchmarking study. Be a part of ... operational strategies for improving customer experience, customer journey, contact channel execution and intelligence, ...
(Date:10/12/2015)... DC (PRWEB) , ... October 12, 2015 , ... ... been selected to receive a Eugene Washington Engagement Award by the Patient-Centered Outcomes ... more effectively with the research community. , The project, entitled “Training Patients ...
(Date:10/12/2015)... ... 12, 2015 , ... The translation for ARIS® 7.x and 9.x to Microsoft ... installations into the Microsoft world. The ARIS models will be fully translated and mapped ... for both IT and Office users it is acknowledged as a competitive alternative to ...
(Date:10/12/2015)... ... October 12, 2015 , ... METTLER TOLEDO is ... processes. In addition, METTLER TOLEDO has collaborated with manufacturing consultant and lean laboratory ... help improve productivity through the identification and elimination of 'hidden' time-wasting activities. Mr ...
Breaking Medicine News(10 mins):